Therapeutics News and Research

RSS

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency and the Army Research Office to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Autism Speaks Autism Treatment Network adds 17 sites in Canada and the U.S

Autism Speaks and Autism Speaks Canada who together form North America's largest autism science and advocacy organization, is pleased to announce the expansion of its Autism Treatment Network to include 17 leading children's hospitals and academic medical centers in the Canada and the U.S.

20 Jan 2011

OXiGENE reaches agreement with warrant holders for warrant exchange

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.

19 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

New study provides insight into developing therapeutics for airway disease

Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.

19 Jan 2011

Meganucleases used to prevent HSV-1 infection

Cellectis, announced today that scientists from Cellectis therapeutics, the French National Center For Medical Research (CNRS) and Institut de la Vision (Paris) have used its proprietary meganucleases to successfully prevent infection of cultured cells by a Herpes Simplex virus (HSV-1).

19 Jan 2011

New patented technique offers unprecedented view of DNA damage

New technology providing the first view of DNA damage throughout the entire human genome developed by Cardiff University scientists could offer a valuable new insight into the development and treatment of conditions like cancer.

19 Jan 2011

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

InQ Biosciences, a provider of innovative technologies for cell growth and research, today announced that a pre-commercial version of its InQ Cell Research System is being utilized in a University of Alabama at Birmingham study evaluating the effects of secondary injury components on brain cells.

19 Jan 2011

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

The Johns Hopkins Brain Science Institute (BSi) announced today that it has entered into an agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) to advance the development of novel therapeutics for neurological and psychiatric diseases.

19 Jan 2011

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

19 Jan 2011

Arrowhead increases ownership in Calando's outstanding equity to 79%

Arrowhead Research Corporation today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Arrowhead now owns approximately 79% of Calando's outstanding equity.

19 Jan 2011

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

The Scripps Research Institute has been awarded $3.17 million over four years to develop compounds that will counteract disruptions of the human biological clock - the circadian rhythm that regulates our patterns of activity and rest over a 24-hour daily cycle.

19 Jan 2011

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.

18 Jan 2011

Study finds miRNAs inhibits prostate cancer metastasis

A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine.

18 Jan 2011

Health Canada requests Osiris for additional information in support of Prochymal approval

Osiris Therapeutics, Inc. today announced that Health Canada has requested additional information in support of the Company's application for approval of Prochymal, a stem cell therapy, for the treatment of graft vs. host disease (GvHD).

14 Jan 2011

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer.

14 Jan 2011

Vanderbilt, Scripps Research form partnership to open new institute

The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.

14 Jan 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.

13 Jan 2011

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded two preclinical services contracts totaling $17.4 million by the National Heart, Lung, and Blood Institute, one of the National Institutes of Health.

13 Jan 2011

Therapeutics News and Research

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Endothelial cells may play a role in controlling cancer behavior: New study

Autism Speaks Autism Treatment Network adds 17 sites in Canada and the U.S

OXiGENE reaches agreement with warrant holders for warrant exchange

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

New study provides insight into developing therapeutics for airway disease

Meganucleases used to prevent HSV-1 infection

New patented technique offers unprecedented view of DNA damage

UAB study uses InQ system to evaluate effects of secondary injury components on brain cells

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Arrowhead increases ownership in Calando's outstanding equity to 79%

Scripps Research receives NIH grant to develop therapies for circadian rhythm disorders

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Study finds miRNAs inhibits prostate cancer metastasis

Health Canada requests Osiris for additional information in support of Prochymal approval

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Vanderbilt, Scripps Research form partnership to open new institute

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

SRI International receives $17.4 million grant to boost treatments for cardiovascular, lung, blood diseases

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News